Recombinant humanized anti-IL-6R monoclonal antibody injection is a biosimilar drug of tocilizumab. Potential indications include rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome, etc. In June 2018, IND application was approved for clinical development. In March 2019, the first phase clinical trial was initiated. It is expected that the first phase of clinical research will be completed by the end of 2019.